SciELO - Scientific Electronic Library Online

 
vol.15 número2Consumo de suplementos nutricionales, actividad física y dismorfia muscular en usuarios de un gimnasio de Asunción, 2022-2023El Sistema de Salud en Paraguay: estructura, funcionamiento y desafíos actuales índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista de salud publica del Paraguay

versión impresa ISSN 2224-6193versión On-line ISSN 2307-3349

Resumen

NAJERA ORTIZ, Juan Carlos; JIMENEZ RANGEL, Andrik  y  BRIONES ARANDA, Alfredo. Effectiveness of Covid-19 Pfizer/BioNTech vaccine through incidence and survival analysis in Mexican health care workers. Rev. salud publica Parag. [online]. 2025, vol.15, n.2, pp.21-28. ISSN 2224-6193.  https://doi.org/10.18004/rspp.2025.ago.05.

Background:

The Covid-19 pandemic promoted the need to evaluate vaccines effectiveness in different groups from those used in the clinical research phases.

Objective:

To analyze the effectiveness of the basic scheme with the Pfizer-BioNTech vaccine through the incidence of Covid-19 and survival analysis, in health workers assigned to a second-level hospital in the State of Chiapas, Mexico.

Material and Methods:

We used an instrument with variables of the following types: sociodemographic, comorbidities, vaccination with Pfizer-BioNTech, disease and Covid-19 diagnosis. The Odds Ratio was calculated to study the relationship of Covid-19 diagnosis with the variables under study, followed by a survival analysis (Kaplan-Meier) and survival curves (Log-Rank).

Results:

Of an inferential sample of 254 individuals, 55.5% were women, with a mean age of 38.8 years; 22.4% were classified as normal-weight; and 18.5% had some comorbidity; 32.3% reported they got ill after taking the complete vaccine schedule. The probability of not getting sick decreased after 7 months. Both, the absence of comorbidities and having Covid-19 sickness between two doses of the vaccine influenced positively in prolonging the time of not having the disease.

Conclusions:

Despite having up to 3 doses of the vaccine, which could increase the protection level against the disease, preventive measures should be strengthened because people possibly increase in confidence when vaccinated, especially in those with comorbidities, due to constant evolution of the virus and the emergence of new variants.

Palabras clave : COVID 19 Vaccine Pfizer BioNTech, Bivalent; vaccine effectiveness; survival analysis; healthcare workers.

        · resumen en Español     · texto en Español     · Español ( pdf )